Clinical pharmacology of oral antidiabetic agents (first of two parts).

Clinical pharmacology of oral antidiabetic agents (second of two parts).

Histamine (first of two parts).

Drug therapy. Clinical Pharmacokinetics (first of two parts).

Myasthenia gravis (first of two parts).

Renal transplantation (first of two parts).

Lung defense mechanisms (first of two parts).

Polymyositis and dermatomyositis (first of two parts).

Clinical pharmacology of the neuromuscular blocking agents.

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.

Clinical pharmacokinetics (second of two parts).

Enzymology of cancer cells (first of two parts).

Binding of drugs to serum albumin (first of two parts).

Basic and clinical concepts related to vitamin D metabolism and action (first of two parts).

Germ-cell testicular cancer in adults (first of two parts).

Dialytic therapy for irreversible uremia (first of two parts).

Catecholamines and neurologic diseases (first of two parts).

Secretin, cholecystokinin and newer gastrointestinal hormones (first of two parts).

Nonosmolar factors affecting renal water excretion (first of two parts).

Perfluorocarbon-based antidiabetic agents.

Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome.

Pharmacogenetics of oral antidiabetic drugs.

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.

Antidiabetic agents and vascular events.

Suggest Documents

Clinical pharmacology of oral antidiabetic agents (second of two parts).

Histamine (first of two parts).

Drug therapy. Clinical Pharmacokinetics (first of two parts).

Myasthenia gravis (first of two parts).

Renal transplantation (first of two parts).

Lung defense mechanisms (first of two parts).

Polymyositis and dermatomyositis (first of two parts).

Clinical pharmacology of the neuromuscular blocking agents.

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.

Clinical pharmacokinetics (second of two parts).

Enzymology of cancer cells (first of two parts).

Binding of drugs to serum albumin (first of two parts).

Basic and clinical concepts related to vitamin D metabolism and action (first of two parts).

Germ-cell testicular cancer in adults (first of two parts).

Dialytic therapy for irreversible uremia (first of two parts).

Catecholamines and neurologic diseases (first of two parts).

Secretin, cholecystokinin and newer gastrointestinal hormones (first of two parts).

Nonosmolar factors affecting renal water excretion (first of two parts).

Perfluorocarbon-based antidiabetic agents.

Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome.

Pharmacogenetics of oral antidiabetic drugs.

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.

Antidiabetic agents and vascular events.

Clinical pharmacology of oral antidiabetic agents (first of two parts).

Recommend Documents

Follow Us